MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

Core Viewpoint - MediWound Ltd. is set to report its financial results for Q4 and the full year of 2025 on March 5, 2026, highlighting its ongoing commitment to transparency and investor communication [1]. Group 1: Financial Reporting - The financial results will cover the fourth quarter and the full year ended December 31, 2025 [1]. - A conference call and live webcast will be held on March 5, 2026, at 8:30 a.m. Eastern Time to discuss these results and provide business highlights [2]. Group 2: Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair [4]. - The company's FDA-approved product, NexoBrid, is used for the enzymatic removal of eschar in thermal burns and is marketed in multiple regions including the United States and European Union [4]. - MediWound's investigational therapy, EscharEx, aims to address chronic wounds and has the potential to set a new standard of care in wound management [4].